Novo Nordisk stock news
On June 18, 2026, Novo Nordisk (NVO) announced positive top--line results from the REDEFINE 3 Phase 3 clinical trial evaluating CagriSema, a fixed--dose combination of cagrilintide and semaglutide. The study met its primary endpoint, demonstrating a mean weight loss of 26% over 68 weeks, significantly outperforming semaglutide monotherapy. These data are expected to form the basis for global regulatory submissions in late 2026, positioning CagriSema as a next--generation treatment to maintain the company's competitive advantage in the obesity market.